Liberate Bio has obtained exclusive and non-exclusive licenses to key patents covering chimeric antigen receptor (CAR) designs optimized for myeloid cells, including monocytes and macrophages.[1] These patents complement the proprietary CAR sequence with proprietary technology for selective in vivo delivery of RNA therapies directly to immune cells.[1] Liberate Bio thereby integrates the necessary components to advance in vivo CAR-M therapies toward clinical evaluation.[1] Myeloid cells have a unique biology distinct from T-cells, therefore CAR constructs optimized for their activation and survival are essential.[1] Walter R. Strapps, Ph.D., Chief Scientific Officer of Liberate Bio, stated that this license agreement significantly strengthens their clinical programs.[1] Combining validated methods of CAR designs with a myeloid-selective LNP platform creates a differentiated and highly integrated approach to in vivo cell therapy.[1]